Skip to main content
Erschienen in: Journal of Diabetes & Metabolic Disorders 1/2021

20.10.2020 | Review article

Epidemiologic pattern of cancers in Iran; current knowledge and future perspective

verfasst von: Esmaeil Mohammadi, Arya Aminorroaya, Nima Fattahi, Sina Azadnajafabad, Nazila Rezaei, Yosef Farzi, Shohreh Naderimagham, Negar Rezaei, Bagher Larijani, Farshad Farzadfar

Erschienen in: Journal of Diabetes & Metabolic Disorders | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Iran is a developing country facing demographic transition. Cancers are among the major non-communicable disorders with remarkable budern on the health-care governing systems. Extended life expectancy of Iranian population, change in living style, as well as promoted diagnostic and treatment methods have resulted into significant malignancies emergence and detection. Understanding the trend of this epidemiologic transition is required for proper allotment of resources. In this manuscript, overall epidemiologic pattern of cancers and their burden transition is reviewed. In addition, more concerning neoplasia (gastrointestinal, breast, thyroid, urologic, and respiratory system cancers) are reviewed in more details.
Literatur
2.
Zurück zum Zitat Kolahdouzan S, Sajadi A, Radmard AR, Khademi H. Five common cancers in Iran. Arch Iran Med. 2010;13(2):143–6. Kolahdouzan S, Sajadi A, Radmard AR, Khademi H. Five common cancers in Iran. Arch Iran Med. 2010;13(2):143–6.
5.
Zurück zum Zitat Salimzadeh H, Ardeshir LF, Abedian S, et al. The trend of national and sub-national burden of gastrointestinal and liver diseases in iran 1990 to 2013, Study Protocol. 2014. Salimzadeh H, Ardeshir LF, Abedian S, et al. The trend of national and sub-national burden of gastrointestinal and liver diseases in iran 1990 to 2013, Study Protocol. 2014.
6.
Zurück zum Zitat Sheidaei A, Gohari K, Kasaeian A, Rezaei N, Mansouri A, Khosravi A, et al. National and subnational patterns of cause of death in Iran 1990–2015: applied methods. Arch Iran Med. 2017;20(1):2–11. Sheidaei A, Gohari K, Kasaeian A, Rezaei N, Mansouri A, Khosravi A, et al. National and subnational patterns of cause of death in Iran 1990–2015: applied methods. Arch Iran Med. 2017;20(1):2–11.
7.
Zurück zum Zitat Farzadfar F, Delavari A, Malekzadeh R, et al. NASBOD 2013: design, definitions, and metrics. Arch Iran Med. 2014;17(1). Farzadfar F, Delavari A, Malekzadeh R, et al. NASBOD 2013: design, definitions, and metrics. Arch Iran Med. 2014;17(1).
9.
Zurück zum Zitat Rezaei N, Pishgar F, Yoosefi M, et al. National and sub-national pediatric cancer mortality in Iran, 2000–2015. Arch Iran Med. 2019;22(6). Rezaei N, Pishgar F, Yoosefi M, et al. National and sub-national pediatric cancer mortality in Iran, 2000–2015. Arch Iran Med. 2019;22(6).
10.
Zurück zum Zitat Pourshams A, Sepanlou SG, Ikuta KS, Bisignano C, Safiri S, Roshandel G, et al. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2019;4(12):934–47.CrossRef Pourshams A, Sepanlou SG, Ikuta KS, Bisignano C, Safiri S, Roshandel G, et al. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2019;4(12):934–47.CrossRef
11.
Zurück zum Zitat Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390(10100):1211–59.CrossRef Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390(10100):1211–59.CrossRef
12.
14.
Zurück zum Zitat Ghasemian A, Ataie-Jafari A, Khatibzadeh S, Mirarefin M, Jafari L, Nejatinamini S, et al. National and sub-national burden of chronic diseases attributable to lifestyle risk factors in Iran 1990-2013; study protocol. Arch Iran Med. 2014;17(3):146–58.PubMed Ghasemian A, Ataie-Jafari A, Khatibzadeh S, Mirarefin M, Jafari L, Nejatinamini S, et al. National and sub-national burden of chronic diseases attributable to lifestyle risk factors in Iran 1990-2013; study protocol. Arch Iran Med. 2014;17(3):146–58.PubMed
15.
Zurück zum Zitat Collaboration GB of DC. Global, regional, and National Cancer Incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524–48. https://doi.org/10.1001/jamaoncol.2016.5688.CrossRef Collaboration GB of DC. Global, regional, and National Cancer Incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524–48. https://​doi.​org/​10.​1001/​jamaoncol.​2016.​5688.CrossRef
16.
Zurück zum Zitat Safiri S, Sepanlou SG, Ikuta KS, Bisignano C, Salimzadeh H, Delavari A, Ansari R, Roshandel G, Merat S, Fitzmaurice C, Force LM, Nixon MR, Abbastabar H, Abegaz KH, Afarideh M, Ahmadi A, Ahmed MB, Akinyemiju T, Alahdab F, Ali R, Alikhani M, Alipour V, Aljunid SM, Almadi MAH, Almasi-Hashiani A, al-Raddadi RM, Alvis-Guzman N, Amini S, Anber NH, Ansari-Moghaddam A, Arabloo J, Arefi Z, Asghari Jafarabadi M, Azadmehr A, Badawi A, Baheiraei N, Bärnighausen TW, Basaleem H, Behzadifar M, Behzadifar M, Belayneh YM, Berhe K, Bhattacharyya K, Biadgo B, Bijani A, Biondi A, Bjørge T, Borzì AM, Bosetti C, Bou-Orm IR, Brenner H, Briko AN, Briko NI, Carreras G, Carvalho F, Castañeda-Orjuela CA, Cerin E, Chiang PPC, Chido-Amajuoyi OG, Daryani A, Davitoiu DV, Demoz GT, Desai R, Dianati nasab M, Eftekhari A, el Sayed I, Elbarazi I, Emamian MH, Endries AY, Esmaeilzadeh F, Esteghamati A, Etemadi A, Farzadfar F, Fernandes E, Fernandes JC, Filip I, Fischer F, Foroutan M, Gad MM, Gallus S, Ghaseni-Kebria F, Ghashghaee A, Gorini G, Hafezi-Nejad N, Haj-Mirzaian A, Haj-Mirzaian A, Hasanpour-Heidari S, Hasanzadeh A, Hassanipour S, Hay SI, Hoang CL, Hostiuc M, Househ M, Ilesanmi OS, Ilic MD, Innos K, Irvani SSN, Islami F, Jaca A, Jafari Balalami N, Jafari delouei N, Jafarinia M, Jahani MA, Jakovljevic M, James SL, Javanbakht M, Jenabi E, Jha RP, Joukar F, Kasaeian A, Kassa TD, Kassaw MW, Kengne AP, Khader YS, Khaksarian M, Khalilov R, Khan EA, Khayamzadeh M, Khazaee-Pool M, Khazaei S, Khosravi Shadmani F, Khubchandani J, Kim D, Kisa A, Kisa S, Kocarnik JM, Komaki H, Kopec JA, Koyanagi A, Kuipers EJ, Kumar V, la Vecchia C, Lami FH, Lopez AD, Lopukhov PD, Lunevicius R, Majeed A, Majidinia M, Manafi A, Manafi N, Manda AL, Mansour-Ghanaei F, Mantovani LG, Mehta D, Meier T, Meles HG, Mendoza W, Mestrovic T, Miazgowski B, Miazgowski T, Mir SM, Mirzaei H, Mohammad KA, Mohammad Gholi Mezerji N, Mohammadian-Hafshejani A, Mohammadoo-Khorasani M, Mohammed S, Mohebi F, Mokdad AH, Monasta L, Moossavi M, Moradi G, Moradpour F, Moradzadeh R, Nahvijou A, Naik G, Najafi F, Nazari J, Negoi I, Nguyen CT, Nguyen TH, Ningrum DNA, Ogbo FA, Olagunju AT, Olagunju TO, Pana A, Pereira DM, Pirestani M, Pourshams A, Poustchi H, Qorbani M, Rabiee M, Rabiee N, Radfar A, Rahmati M, Rajati F, Rawaf DL, Rawaf S, Reiner Jr RC, Renzaho AMN, Rezaei N, Rezapour A, Saad AM, Saadatagah S, Saddik B, Salehi F, Salehi Zahabi S, Salz I, Samy AM, Sanabria J, Santric Milicevic MM, Sarveazad A, Satpathy M, Schneider IJC, Sekerija M, Shaahmadi F, Shabaninejad H, Shamsizadeh M, Sharafi Z, Sharif M, Sharifi A, Sheikhbahaei S, Shirkoohi R, Siddappa Malleshappa SK, Silva DAS, Sisay M, Smarandache CG, Soofi M, Soreide K, Soshnikov S, Starodubov VI, Subart ML, Sullman MJM, Tabarés-Seisdedos R, Taherkhani A, Tesfay B, Topor-Madry R, Traini E, Tran BX, Tran KB, Ullah I, Uthman OA, Vacante M, Vahedian-Azimi A, Valli A, Varavikova E, Vujcic IS, Westerman R, Yazdi-Feyzabadi V, Yisma E, Yu C, Zadnik V, Zahirian Moghadam T, Zaki L, Zandian H, Zhang ZJ, Murray CJL, Naghavi M, Malekzadeh R The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol 2019;4(12):913–933. https://doi.org/10.1016/S2468-1253(19)30345-0. Safiri S, Sepanlou SG, Ikuta KS, Bisignano C, Salimzadeh H, Delavari A, Ansari R, Roshandel G, Merat S, Fitzmaurice C, Force LM, Nixon MR, Abbastabar H, Abegaz KH, Afarideh M, Ahmadi A, Ahmed MB, Akinyemiju T, Alahdab F, Ali R, Alikhani M, Alipour V, Aljunid SM, Almadi MAH, Almasi-Hashiani A, al-Raddadi RM, Alvis-Guzman N, Amini S, Anber NH, Ansari-Moghaddam A, Arabloo J, Arefi Z, Asghari Jafarabadi M, Azadmehr A, Badawi A, Baheiraei N, Bärnighausen TW, Basaleem H, Behzadifar M, Behzadifar M, Belayneh YM, Berhe K, Bhattacharyya K, Biadgo B, Bijani A, Biondi A, Bjørge T, Borzì AM, Bosetti C, Bou-Orm IR, Brenner H, Briko AN, Briko NI, Carreras G, Carvalho F, Castañeda-Orjuela CA, Cerin E, Chiang PPC, Chido-Amajuoyi OG, Daryani A, Davitoiu DV, Demoz GT, Desai R, Dianati nasab M, Eftekhari A, el Sayed I, Elbarazi I, Emamian MH, Endries AY, Esmaeilzadeh F, Esteghamati A, Etemadi A, Farzadfar F, Fernandes E, Fernandes JC, Filip I, Fischer F, Foroutan M, Gad MM, Gallus S, Ghaseni-Kebria F, Ghashghaee A, Gorini G, Hafezi-Nejad N, Haj-Mirzaian A, Haj-Mirzaian A, Hasanpour-Heidari S, Hasanzadeh A, Hassanipour S, Hay SI, Hoang CL, Hostiuc M, Househ M, Ilesanmi OS, Ilic MD, Innos K, Irvani SSN, Islami F, Jaca A, Jafari Balalami N, Jafari delouei N, Jafarinia M, Jahani MA, Jakovljevic M, James SL, Javanbakht M, Jenabi E, Jha RP, Joukar F, Kasaeian A, Kassa TD, Kassaw MW, Kengne AP, Khader YS, Khaksarian M, Khalilov R, Khan EA, Khayamzadeh M, Khazaee-Pool M, Khazaei S, Khosravi Shadmani F, Khubchandani J, Kim D, Kisa A, Kisa S, Kocarnik JM, Komaki H, Kopec JA, Koyanagi A, Kuipers EJ, Kumar V, la Vecchia C, Lami FH, Lopez AD, Lopukhov PD, Lunevicius R, Majeed A, Majidinia M, Manafi A, Manafi N, Manda AL, Mansour-Ghanaei F, Mantovani LG, Mehta D, Meier T, Meles HG, Mendoza W, Mestrovic T, Miazgowski B, Miazgowski T, Mir SM, Mirzaei H, Mohammad KA, Mohammad Gholi Mezerji N, Mohammadian-Hafshejani A, Mohammadoo-Khorasani M, Mohammed S, Mohebi F, Mokdad AH, Monasta L, Moossavi M, Moradi G, Moradpour F, Moradzadeh R, Nahvijou A, Naik G, Najafi F, Nazari J, Negoi I, Nguyen CT, Nguyen TH, Ningrum DNA, Ogbo FA, Olagunju AT, Olagunju TO, Pana A, Pereira DM, Pirestani M, Pourshams A, Poustchi H, Qorbani M, Rabiee M, Rabiee N, Radfar A, Rahmati M, Rajati F, Rawaf DL, Rawaf S, Reiner Jr RC, Renzaho AMN, Rezaei N, Rezapour A, Saad AM, Saadatagah S, Saddik B, Salehi F, Salehi Zahabi S, Salz I, Samy AM, Sanabria J, Santric Milicevic MM, Sarveazad A, Satpathy M, Schneider IJC, Sekerija M, Shaahmadi F, Shabaninejad H, Shamsizadeh M, Sharafi Z, Sharif M, Sharifi A, Sheikhbahaei S, Shirkoohi R, Siddappa Malleshappa SK, Silva DAS, Sisay M, Smarandache CG, Soofi M, Soreide K, Soshnikov S, Starodubov VI, Subart ML, Sullman MJM, Tabarés-Seisdedos R, Taherkhani A, Tesfay B, Topor-Madry R, Traini E, Tran BX, Tran KB, Ullah I, Uthman OA, Vacante M, Vahedian-Azimi A, Valli A, Varavikova E, Vujcic IS, Westerman R, Yazdi-Feyzabadi V, Yisma E, Yu C, Zadnik V, Zahirian Moghadam T, Zaki L, Zandian H, Zhang ZJ, Murray CJL, Naghavi M, Malekzadeh R The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol 2019;4(12):913–933. https://​doi.​org/​10.​1016/​S2468-1253(19)30345-0.
17.
19.
Zurück zum Zitat Collaboration GB of DC. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524–48. https://doi.org/10.1001/jamaoncol.2016.5688.CrossRef Collaboration GB of DC. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524–48. https://​doi.​org/​10.​1001/​jamaoncol.​2016.​5688.CrossRef
22.
Zurück zum Zitat Harirchi I, Karbakhsh M, Kashefi A, Momtahen AJ. Breast cancer in Iran: results of a multi-center study. Asian Pac J Cancer Prev. 2004;5(1):24–7.PubMed Harirchi I, Karbakhsh M, Kashefi A, Momtahen AJ. Breast cancer in Iran: results of a multi-center study. Asian Pac J Cancer Prev. 2004;5(1):24–7.PubMed
25.
Zurück zum Zitat Esmaeimzadeh N, Salahi-Moghaddam A, Khoshdel A. Geographic distribution of important cancers in Iran. Hormozgan Med J. 2015;19(2):66–76. Esmaeimzadeh N, Salahi-Moghaddam A, Khoshdel A. Geographic distribution of important cancers in Iran. Hormozgan Med J. 2015;19(2):66–76.
26.
Zurück zum Zitat Haghpanah V, Soliemanpour B, Heshmat R, Mosavi-Jarrahi AR, Tavangar SM, Malekzadeh R, et al. Endocrine cancer in Iran: based on cancer registry system. Indian J Cancer. 2006;43(2):80–5.CrossRef Haghpanah V, Soliemanpour B, Heshmat R, Mosavi-Jarrahi AR, Tavangar SM, Malekzadeh R, et al. Endocrine cancer in Iran: based on cancer registry system. Indian J Cancer. 2006;43(2):80–5.CrossRef
27.
Zurück zum Zitat Farzadfar F, Peykari N, Larijani B, Rahimzadeh S, Rezaei-Darzi E, Saeedi MS. A comprehensive study on national and sub national trend in thyroid cancer prevalence in the iranian population, 1990–2010. Iran J Diabetes Metab. 2016;15(2):91–100. Farzadfar F, Peykari N, Larijani B, Rahimzadeh S, Rezaei-Darzi E, Saeedi MS. A comprehensive study on national and sub national trend in thyroid cancer prevalence in the iranian population, 1990–2010. Iran J Diabetes Metab. 2016;15(2):91–100.
30.
Zurück zum Zitat Ebrahimi H, Amini E, Pishgar F, Moghaddam SS, Nabavizadeh B, Rostamabadi Y, et al. Global, regional and national burden of bladder cancer, 1990 to 2016: results from the GBD study 2016. J Urol. 2019;201(5):893–901.CrossRef Ebrahimi H, Amini E, Pishgar F, Moghaddam SS, Nabavizadeh B, Rostamabadi Y, et al. Global, regional and national burden of bladder cancer, 1990 to 2016: results from the GBD study 2016. J Urol. 2019;201(5):893–901.CrossRef
32.
Zurück zum Zitat Chesnais J-C. The demographic transition: stages, patterns, and economic implications. OUP Cat. 1992. Chesnais J-C. The demographic transition: stages, patterns, and economic implications. OUP Cat. 1992.
Metadaten
Titel
Epidemiologic pattern of cancers in Iran; current knowledge and future perspective
verfasst von
Esmaeil Mohammadi
Arya Aminorroaya
Nima Fattahi
Sina Azadnajafabad
Nazila Rezaei
Yosef Farzi
Shohreh Naderimagham
Negar Rezaei
Bagher Larijani
Farshad Farzadfar
Publikationsdatum
20.10.2020
Verlag
Springer International Publishing
Erschienen in
Journal of Diabetes & Metabolic Disorders / Ausgabe 1/2021
Elektronische ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-020-00654-6

Weitere Artikel der Ausgabe 1/2021

Journal of Diabetes & Metabolic Disorders 1/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.